167 related articles for article (PubMed ID: 35247929)
1. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
Hunihan L; Zhao D; Lazowski H; Li M; Qian Y; Abriola L; Surovtseva YV; Muthusamy V; Tanoue LT; Rothberg BEG; Schalper KA; Herbst RS; Wilson FH
Clin Cancer Res; 2022 Jul; 28(14):3091-3103. PubMed ID: 35247929
[TBL] [Abstract][Full Text] [Related]
2. All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer.
Moorthi S; Berger AH
Clin Cancer Res; 2022 Jul; 28(14):2983-2985. PubMed ID: 35512219
[TBL] [Abstract][Full Text] [Related]
3. Identification of a RAS-activating
Cooper AJ; Kobayashi Y; Kim D; Clifford SE; Kravets S; Dahlberg SE; Chambers ES; Li J; Rangachari D; Nguyen T; Costa DB; Rabin MS; Wagle N; Sholl LM; Jänne PA; Oxnard GR
Clin Cancer Res; 2020 Aug; 26(15):4072-4079. PubMed ID: 32312893
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
[TBL] [Abstract][Full Text] [Related]
5. Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
Zhu LY; Yuan JB; Zhang L; He CX; Lin X; Xu B; Jin GH
Cancer Res; 2022 Nov; 82(22):4153-4163. PubMed ID: 36098964
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of Oncogenic
Cai D; Choi PS; Gelbard M; Meyerson M
Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
[TBL] [Abstract][Full Text] [Related]
7. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional profiling reveals functional links between RasGrf1 and Pttg1 in pancreatic beta cells.
Manyes L; Arribas M; Gomez C; Calzada N; Fernandez-Medarde A; Santos E
BMC Genomics; 2014 Nov; 15():1019. PubMed ID: 25421944
[TBL] [Abstract][Full Text] [Related]
9. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.
Sacco E; Metalli D; Spinelli M; Manzoni R; Samalikova M; Grandori R; Morrione A; Traversa S; Alberghina L; Vanoni M
Biotechnol Adv; 2012; 30(1):233-43. PubMed ID: 21620943
[TBL] [Abstract][Full Text] [Related]
10. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
11. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas.
Tarnowski M; Schneider G; Amann G; Clark G; Houghton P; Barr FG; Kenner L; Ratajczak MZ; Kucia M
Int J Oncol; 2012 Sep; 41(3):995-1004. PubMed ID: 22752028
[TBL] [Abstract][Full Text] [Related]
12. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
13. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; Saigi M; Alameda D; Gomez-Mariano G; Martinez-Delgado B; Alburquerque-Bejar JJ; Carretero J; Tonda R; Esteve-Codina A; Catala I; Palmero R; Jove M; Lazaro C; Patiño-Garcia A; Gil-Bazo I; Verdura S; Teulé A; Torres-Lanzas J; Sidransky D; Reguart N; Pio R; Juan-Vidal O; Nadal E; Felip E; Montuenga LM; Sanchez-Cespedes M
Ann Oncol; 2020 Feb; 31(2):274-282. PubMed ID: 31959344
[TBL] [Abstract][Full Text] [Related]
15. miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1.
Deng D; Xue L; Shao N; Qu H; Wang Q; Wang S; Xia X; Yang Y; Zhi F
Tumour Biol; 2016 Mar; 37(3):3331-40. PubMed ID: 26440052
[TBL] [Abstract][Full Text] [Related]
16. The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.
Abreu JR; de Launay D; Sanders ME; Grabiec AM; van de Sande MG; Tak PP; Reedquist KA
Arthritis Res Ther; 2009; 11(4):R121. PubMed ID: 19678938
[TBL] [Abstract][Full Text] [Related]
17. The ERBB network facilitates KRAS-driven lung tumorigenesis.
Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Daemen A; Cooper JE; Myrta S; Wongchenko MJ; Lin E; Long JE; Foreman O; Modrusan Z; Tremayne JR; de la Cruz CC; Merchant M; Martin SE; Yan Y; Junttila MR
Clin Cancer Res; 2021 Feb; 27(4):1162-1173. PubMed ID: 33023953
[TBL] [Abstract][Full Text] [Related]
19. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.
Li S; Choi YL; Gong Z; Liu X; Lira M; Kan Z; Oh E; Wang J; Ting JC; Ye X; Reinhart C; Liu X; Pei Y; Zhou W; Chen R; Fu S; Jin G; Jiang A; Fernandez J; Hardwick J; Kang MW; I H; Zheng H; Kim J; Mao M
J Thorac Oncol; 2016 Dec; 11(12):2129-2140. PubMed ID: 27615396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
